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p < 0.0001. Subjects with lower scores had worse survival: HR
1.6 (95% CI 1.2, 2.0), p < 0.0002. CONCLUSION: QoL mea-
sures underestimate utilities. The weighted global QoL and
utility scores had discriminative and predictive validity in
advanced cancer. Our work enables QoL data obtained with a
simple questionnaire to be converted into optimally weighted
measures that can be used in clinical trials to: describe the net
effect of cancer treatments on QoL; evaluate trade-offs between
quality and quantity of life using quality-adjusted survival analy-
sis; and do cost-effectiveness analyses based on cancer patients’
preferences.
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OBJECTIVES: To analyze the effectiveness of Darbepoetin alpha
and Epoetin alpha administered in patients with chemotherapy-
induced anaemia (CIA) in the German setting considering the
dosing schedules recommended in Germany. METHODS: Pub-
lished prospective, randomized and controlled studies with either
Epoetin alpha administered once weekly (EPO-QW), Darbepo-
etin administered QW (DARB-QW) and once every three weeks
(DARB-Q3W) were extracted. Mean haemoglobin area-under-
the-change-curve (HB-AUC) was selected as the effectiveness
parameter, calculated by inclusion of all available haemoglobin
values in the chosen time frame of 12 weeks. Mean administered
doses and transfusion requirements were analysed. Number of
study patients were accounted for. RESULTS: Eleven study arms
were identiﬁed satisfying the inclusion criteria. Mean baseline
HB for EPO-QW, DARB-QW and DARB-Q3W varied between
9.5–10.4 g/dl, 9.4–9.9 g/dl, and 9.8–9.9 g/dl respectively. The
increase in HB levels from baseline to week 12 varied between
about 1.0 g/dl–2.9 g/dl, 1.1 g/dl–1.6 g/dl, and about 1.0 g/dl.
Calculated mean HB-AUC value for EPO-QW, DARB-QW
and DARB-Q3W were 11.75, 8.84 and 8.08, respectively.
Mean administered doses reported were 39,949 IU / week and
42,714 IU / week for EPO-QW, 2.2 mg/kg weekly, 1.59 mg/kg
weekly, 2.05 mg/kg weekly for DARB-QW and 1.87 mg/kg weekly
mean dose per kg for DARB-Q3W. Information on transfusion
rates differed, for two study-arms transfusion requirements were
not reported at all. CONCLUSION: Comparative studies are not
available for the recommended and labeled regimens in Germany.
Quality and amount of reported data needed for comparing
clinical effectiveness from different study arms differ very much.
Administered doses, transfusion rates and detailed HB increase
were not available for all studies. Considering HB-AUC as
the key comparison criterium Epoetin alpha administered once
weekly is more effective.
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OBJECTIVES: Despite demonstrated efﬁcacy of anthrayclines in
metastatic breast cancer (MBC), strong evidence links these
agents to development of reduced left ventricular ejection frac-
tion (LVEF) and congestive heart failure (CHF). We examined the
cost-effectiveness of using pegylated lipisomal doxorubicin (PLD)
to reduce cardiotoxicity. METHODS: A Markov model was
developed to simulate the use of PLD vs. conventional doxoru-
bicin (DOX) in the ﬁrst 48 weeks after initiation of therapy. Our
reference case was a 58 year old female newly diagnosed with
MBC. Data from a large-scale clinical trial was used to model the
incidence of CHF. The perspective was the provincial authority in
Ontario, Canada. Costs included direct costs of chemotherapy,
oncology and hospital services for managing MBC, as well as
medical management for treating cardiotoxicity. Since trial data
showed that patients with prior anthracycline exposure (15%)
had a relative risk of 2.8 for LVEF, and 4.1 for progression to
CHF, we adjusted for prior anthracycline exposure which is
greater in the adjuvant setting (80% in Ontario). A previously
developed cardiotoxicity risk model was used to identify high-
risk patients. Analyses were performed for: 1) all patients, 2)
subset of high-risk patients. RESULTS: For DOX, 40% experi-
enced cardiotoxicity, with 18% developing CHF. These rates
were 54% and 33% in high-risk patients. For PLD, no patients
developed CHF, but 9% overall and 14% of high-risk patients
developed LVEF. Using PLD instead of DOX was associated with
an incremental cost of CAD$75,513 per patient spared CHF,
$49,952 in high-risk patients. CONCLUSION: In the ﬁrst treat-
ment year, the greatest cost-effectiveness gain was avoidance of
CHF in high-risk patients. In Ontario, where the vast majority of
patients are high-risk, a large percentage of patients would be
expected to avoid CHF by using pegylated lipisomal doxorubicin
instead of conventional doxorubicin.
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OBJECTIVES: To measure the mean incremental differences in
health services utilization and costs for individuals infected with
HIV compared with individuals not infected with HIV who
reside in the Downtown Eastside (DTES) of Vancouver, Canada.
METHODS: We utilized data from the Community Health And
Safety Evaluation (CHASE) Project, a prospective cohort study
undertaken to measure health care utilization. A representative
sample of residents living in the DTES were recruited beginning
February 2003 and followed until March 31, 2004. Self-reported
information was collected at baseline and included sections on
sociodemographics, education, employment, housing, and illicit
drug use. This information was linked to administrative health
records on HIV-status, hospitalizations, outpatient consultations,
and dispensed medications. Health expenditures included costs
of hospitalizations (estimated using length of stay and the mean
per-diem), outpatient visits and medications and were analyzed
using random effects linear regression models and reported in
2004 $CDN. RESULTS: The analysis consisted of 2,905 indi-
viduals who were successfully linked with at least one of the
linked databases. There were 459 (15.8%) HIV-positive and
2456 HIV-negative participants. All utilization and cost estimates
were signiﬁcantly higher for individuals infected with HIV, both
crudely and after adjustment. Individuals infected with HIV had
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an annual mean additional 42.1 outpatient consultations (95%
CI: 36.4–57.9) and 2.4 inpatient days (95% CI: 1.2–3.6). This
resulted in an estimated increase in health expenditures of $3140
CAN (95% CI: 2052–4225). CONCLUSION: Using high quality
administrative health data we found that, among individuals
living in Vancouver’s DTES (Canada’a poorest postal code),
infection with HIV resulted in increased mean utilization of
health services and expenditures. This has implications for social
and health conditions associated with poverty in communities
with high HIV prevalence. The quantitative estimates can be
useful when evaluating programs designed to prevent and treat
HIV amongst persons living in impoverished areas.
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OBJECTIVES: Rituximab maintenance therapy (RM) has been
shown to signiﬁcantly extend overall survival (OS) and pro-
gression free survival (PFS) in relapsed/refractory follicular
lymphoma (FL) in the pivotal trial EORTC20981. The purpose
of this study was to assess, from the French Sickness Funds
perspective, cost-effectiveness and cost-utility of RM after
induction therapy versus current standard practice (observation).
METHODS: A 3 health state lifetime transition model (30 years)
was developed comparing RM and observation (Obs). PFS and
OS were derived from the trial EORTC20981 with a median
follow-up of 28 months and extrapolated from 2-year Kaplan-
Meier curves using a Weibull distribution and were conserva-
tively assumed to last only 5 years. Utility data were derived from
a multicentric observational study using the EQ-5D question-
naire. Direct medical costs derived from French ofﬁcial sources.
Costs were discounted at 3% and sensitivity analyses were per-
formed. RESULTS: RM is effective in the management of
relapsed/resistant FL. The results showed that life expectancy
and QALY were increased respectively by 22% and 30% in
patients treated with RM. Incremental cost-effectiveness ratio
(ICER) was €7,612 per life year gained. The cost per QALY
gained was €8,729. In one-way sensitivity analysis most of ratios
fell within the range of €7,000 to €12,000 (the ICERs ranged
from €5,700 to €43,300 per LYG and from 6,800€ to €49,700
per QALY). The frequency and cost of treatments upon relapse
were identiﬁed as drivers for the model. Palliative care, transpor-
tation and indirect costs such as productivity loss were not
included in the analysis. It was a conservative approach because
it was expected that patients under RM would have less relapse
and better life expectancy than those in observation. CONCLU-
SION: RM is a cost-effective strategy in the management of
relapsed/refractory FL in France with an ICER largely below the
threshold commonly cited in such analysis.
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